Skip to Main content Skip to Navigation
Journal articles

Ibrutinib monotherapy for relapse or refractory primary CNS lymphoma and primary vitreoretinal lymphoma Final analysis of the phase II ‘proof-of-concept’ iLOC study by the Lymphoma study association (LYSA) and the French oculo-cerebral lymphoma (LOC) network

Complete list of metadatas

https://hal-univ-rennes1.archives-ouvertes.fr/hal-02182035
Contributor : Laurent Jonchère <>
Submitted on : Friday, July 12, 2019 - 3:32:21 PM
Last modification on : Monday, January 27, 2020 - 5:10:11 PM

Identifiers

Citation

C. Soussain, S. Choquet, M. Blonski, D. Leclercq, C. Houillier, et al.. Ibrutinib monotherapy for relapse or refractory primary CNS lymphoma and primary vitreoretinal lymphoma Final analysis of the phase II ‘proof-of-concept’ iLOC study by the Lymphoma study association (LYSA) and the French oculo-cerebral lymphoma (LOC) network. European Journal of Cancer, Elsevier, 2019, 117, pp.121-130. ⟨10.1016/j.ejca.2019.05.024⟩. ⟨hal-02182035⟩

Share

Metrics

Record views

32